問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Kaoshiung Chang Gung Memorial Hospital of the C.G.M.F. (在職)

Division of Thoracic Medicine

Division of Radiation Therapy

Division of Hematology & Oncology

更新時間：2023-09-19

黃俊杰
  • Co-Principal Investigator
  • Clinical Trial Experience (year)

Recruiting Trial

2Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

黃俊杰

List

4Cases

2021-06-30 - 2023-11-14

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Not yet recruiting3Sites

Recruiting2Sites

2020-03-01 - 2032-06-30

Phase III

Active
A Phase 3, Randomized, Double-blind, Placebo-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) Versus CRT Alone in Participants With Muscle-invasive Bladder Cancer (MIBC) (KEYNOTE-992)

  • Condition/Disease

    Muscle-invasive Bladder Cancer (MIBC)

  • Test Drug

    Pembrolizumab (MK-3475) KEYTRUDA

Participate Sites
7Sites

Recruiting7Sites

2020-04-01 - 2025-11-26

Phase III

Completed
A Phase 3, Randomized, Open Label Study to Compare Nivolumab Plus Concurrent Chemoradiotherapy (CCRT) Followed by Nivolumab Plus Ipilimumab or Nivolumab Plus CCRT Followed by Nivolumab vs CCRT Followed by Durvalumab in Previously Untreated, Locally Advanced Non-small Cell Lung Cancer (LA NSCLC)

  • Condition/Disease

    Previously Untreated, Locally Advanced Non-small Cell Lung Cancer

  • Test Drug

    OPDIVO (nivolumab) Injection 10mg/mL OPDIVO (nivolumab) Injection 10mg/mL YERVOY (ipilimumab) Injection 5mg/mL YERVOY (ipilimumab) Injection 5mg/mL

Participate Sites
7Sites

Not yet recruiting1Sites

Recruiting6Sites

2019-09-01 - 2019-08-06

Phase III

Regarding tislelizumab (BGB-A317) combined with chemotherapy and radiotherapy followed by tislelizumab monotherapy for use in newly diagnosed, locally advanced, unresectable stage III non-small cell lung cancer subjects for a phase 3, random assignment, double blind, Placebo controlled trial.

  • Condition/Disease

    NSCLC

  • Test Drug

    Tislelizumab

Participate Sites
8Sites

Recruiting3Sites

Terminated5Sites

聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB